Alnylam Pharmaceuticals, Inc. - stock earnings
ALNY Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 BeforeMarket | -0.16 / -1.21 | - | 494.3 million / 435.7 million | - |
ALNY Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -137.9 million USD | 439.7 million USD |
| 2023Q3 | 147.8 million USD | 750.5 million USD |
| 2023Q2 | -276.0 million USD | 318.8 million USD |
| 2023Q1 | -174.1 million USD | 319.3 million USD |
| 2022Q4 | -207.5 million USD | 335.0 million USD |
| 2022Q3 | -405.9 million USD | 264.3 million USD |
| 2022Q2 | -277.4 million USD | 224.8 million USD |
| 2022Q1 | -240.3 million USD | 213.3 million USD |
| 2021Q4 | -258.5 million USD | 258.5 million USD |
| 2021Q3 | -204.5 million USD | 187.6 million USD |
| 2021Q2 | -189.6 million USD | 220.6 million USD |
| 2021Q1 | -200.3 million USD | 177.6 million USD |
| 2020Q4 | -243.5 million USD | 163.6 million USD |
| 2020Q3 | -253.3 million USD | 125.9 million USD |
| 2020Q2 | -179.2 million USD | 104.0 million USD |
| 2020Q1 | -182.2 million USD | 99.5 million USD |
| 2019Q4 | -276.2 million USD | 71.7 million USD |
| 2019Q3 | -208.5 million USD | 70.1 million USD |
| 2019Q2 | -219.5 million USD | 44.7 million USD |
| 2019Q1 | -181.9 million USD | 33.3 million USD |
| 2018Q4 | -211.4 million USD | 21.0 million USD |
| 2018Q3 | -245.3 million USD | 2.1 million USD |
| 2018Q2 | -163.6 million USD | 29.9 million USD |
| 2018Q1 | -141.2 million USD | 21.9 million USD |
| 2017Q4 | -142.2 million USD | 37.9 million USD |
| 2017Q3 | -122.9 million USD | 17.1 million USD |
| 2017Q2 | -118.4 million USD | 15.9 million USD |
| 2017Q1 | -107.3 million USD | 19.0 million USD |
| 2016Q4 | -112.9 million USD | 17.5 million USD |
| 2016Q3 | -104.1 million USD | 13.7 million USD |
| 2016Q2 | -90.1 million USD | 8.7 million USD |
| 2016Q1 | -103.0 million USD | 7.3 million USD |
| 2015Q4 | -90.7 million USD | 7.6 million USD |
| 2015Q3 | -76.8 million USD | 6.3 million USD |
| 2015Q2 | -71.8 million USD | 8.7 million USD |
| 2015Q1 | -50.8 million USD | 18.5 million USD |
| 2014Q4 | -21.4 million USD | 24.0 million USD |
| 2014Q3 | -44.0 million USD | 11.0 million USD |
| 2014Q2 | -44.1 million USD | 7.3 million USD |
| 2014Q1 | -250.9 million USD | 8.3 million USD |
| 2013Q4 | -32.4 million USD | 10.8 million USD |
| 2013Q3 | -29.7 million USD | 9.0 million USD |
| 2013Q2 | -18.2 million USD | 8.7 million USD |
| 2013Q1 | -9.0 million USD | 18.6 million USD |
| 2012Q4 | -62.2 million USD | 8.5 million USD |
| 2012Q3 | -19.5 million USD | 16.8 million USD |
| 2012Q2 | -13.0 million USD | 20.9 million USD |
| 2012Q1 | -11.4 million USD | 20.6 million USD |
| 2011Q4 | -14.3 million USD | 20.5 million USD |
| 2011Q3 | -13.2 million USD | 20.8 million USD |
| 2011Q2 | -13.8 million USD | 20.6 million USD |
| 2011Q1 | -16.3 million USD | 20.9 million USD |
| 2010Q4 | -6.9 million USD | 21.2 million USD |
| 2010Q3 | -9.6 million USD | 27.7 million USD |
| 2010Q2 | -14.6 million USD | 26.6 million USD |
| 2010Q1 | -12.3 million USD | 24.6 million USD |
| 2009Q4 | -7.8 million USD | 26.6 million USD |
| 2009Q3 | -9.2 million USD | 24.2 million USD |
| 2009Q2 | -22.7 million USD | 24.6 million USD |
| 2009Q1 | -7.9 million USD | 25.1 million USD |
| 2008Q4 | -9.4 million USD | 24.4 million USD |
| 2008Q3 | -2.9 million USD | 25.7 million USD |
| 2008Q2 | -12.8 million USD | 23.8 million USD |
| 2008Q1 | -1.2 million USD | 22.2 million USD |
| 2007Q4 | 1.7 million USD | 18.2 million USD |
| 2007Q3 | -52.8 million USD | 16.3 million USD |
| 2007Q2 | -12.7 million USD | 9.1 million USD |
| 2007Q1 | -21.6 million USD | 7.2 million USD |
| 2006Q4 | -8.4 million USD | 7.0 million USD |
| 2006Q3 | -7.4 million USD | 8.2 million USD |
| 2006Q2 | -9.9 million USD | 6.0 million USD |
| 2006Q1 | -8.9 million USD | 5.7 million USD |
| 2005Q4 | -14.5 million USD | 1.6 million USD |
| 2005Q3 | -10.7 million USD | 1.4 million USD |
| 2005Q2 | -11.1 million USD | 1.1 million USD |
| 2005Q1 | -6.6 million USD | 1.6 million USD |
| 2004Q4 | -5.7 million USD | 2.6 million USD |
| 2004Q3 | -6.4 million USD | 1.4 million USD |
| 2004Q2 | -7.0 million USD | 131000 USD |
| 2004Q1 | -13.6 million USD | 134000 USD |
| 2003Q4 | -6.3 million USD | 44000 USD |
| 2003Q3 | -6.3 million USD | 44000 USD |
| 2003Q2 | -3.2 million USD | ? USD |
| 2003Q1 | -2.2 million USD | ? USD |
ALNY Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -440.2 million USD | 1.8 billion USD |
| 2022 | -1.1 billion USD | 1.0 billion USD |
| 2021 | -852.8 million USD | 844.3 million USD |
| 2020 | -858.3 million USD | 492.9 million USD |
| 2019 | -886.1 million USD | 219.8 million USD |
| 2018 | -761.5 million USD | 74.9 million USD |
| 2017 | -490.9 million USD | 89.9 million USD |
| 2016 | -410.1 million USD | 47.2 million USD |
| 2015 | -290.1 million USD | 41.1 million USD |
| 2014 | -360.4 million USD | 50.6 million USD |
| 2013 | -89.2 million USD | 47.2 million USD |
| 2012 | -106.0 million USD | 66.7 million USD |
| 2011 | -57.6 million USD | 82.8 million USD |
| 2010 | -43.5 million USD | 100.0 million USD |
| 2009 | -47.6 million USD | 100.5 million USD |
| 2008 | -26.2 million USD | 96.2 million USD |
| 2007 | -85.5 million USD | 50.9 million USD |
| 2006 | -34.6 million USD | 26.9 million USD |
| 2005 | -42.9 million USD | 5.7 million USD |
| 2004 | -32.7 million USD | 4.3 million USD |
| 2003 | -25.0 million USD | 176000 USD |
| 2002 | -4.1 million USD | ? USD |
ALNY
Price: $152.33
52 week price:
Earnings Per Share: -3.52 USD
P/E Ratio: -41.14
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 712302
Ebitda: -143.6 millionMarket Capitalization: 19.2 billion